Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

Trial Profile

Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Growth disorders
  • Focus Therapeutic Use
  • Acronyms EPASOS
  • Most Recent Events

    • 26 Sep 2017 Planned End Date changed from 1 Dec 2021 to 1 Feb 2016.
    • 22 Feb 2016 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.
    • 08 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top